The AI & Digitalisation Zone will be hosted in the exhibition area and will serve as the central hub for AI-driven drug discovery, digital R&D, and next-generation platform technologies, bringing together innovators such as Recursion, Insitro, QT Sense, and other leaders across AI discovery platforms, cloud infrastructure, automation, bioinformatics, digital biology, academic hubs, and strategic pharma tech partners. This interactive space will feature poster presentations, live demos, and short tech talks, alongside an AI Networking Lounge and a coffee cart to foster meaningful connections and collaboration. 

Join fellow industry leaders for an exclusive VIP networking dinner designed to foster meaningful connections and conversations across the drug discovery, formulation, and delivery community. Limited seating available.

Bringing together leaders from drug discovery, formulation, and drug delivery, these interactive roundtables are designed to break down traditional silos and foster cross-functional collaboration. Through open discussion and peer-to-peer exchange, participants will explore how earlier alignment across target discovery, molecule design, developability, and delivery can improve decision-making, reduce risk, and ultimately accelerate the development of successful medicines:

Our 'Women in Drug Discovery & Development' panel discussion brings together leaders and rising talent to explore career progression, leadership, and the evolving role of women across the drug discovery and development landscape. Through open discussion, the session will examine strategies for overcoming barriers, fostering mentorship and sponsorship, and driving greater diversity and influence in scientific innovation and decision-making.

Richard Bonneau,
VP and Global Head of AI for Drug Discovery, Genentech/Roche,

Richard Bonneau is VP and Global Head of AI for Drug Discovery at Genentech and Roche. An internationally recognised leader in computational biology, his pioneering work in machine learning, protein structure prediction, and systems biology has helped transform how new medicines are discovered and developed. 

Joseph Wu,
Director, Stanford Cardiovascular Institute & Co-Founder, Greenstone Biosciences

Joseph Wu is Director of the Stanford Cardiovascular Institute and one of the world's leading innovators in stem cell research, organoids, and AI-enabled drug discovery. A member of the National Academy of Medicine, his work is pioneering new approaches to disease modelling, precision medicine, and next-generation therapeutic development. 

Closed-door sessions offer an exclusive space for candid, off-the-record discussions. Connect with peers, share insights, and tackle the industry’s toughest challenges. Designed for executives shaping the future of the sector:  

•  Where Smart Capital Meets Science: Investing In The Next Wave Of Drug Discovery Innovation 
Moderated by Sam Tetlow, Founder & Chief Executive Officer, Grant Engine 

•  The Real Impact Of AI On Drug Discovery Workflows
Featuring Insitro & Eli Lilly

•  Partnerships, Platforms Or Acquisitions: What Is The Winning Model For Brain Health Innovation?
Moderated by Denise Steckel, Head of Clinical Collaborations Development, Genentech